JP2019514913A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514913A5
JP2019514913A5 JP2018556332A JP2018556332A JP2019514913A5 JP 2019514913 A5 JP2019514913 A5 JP 2019514913A5 JP 2018556332 A JP2018556332 A JP 2018556332A JP 2018556332 A JP2018556332 A JP 2018556332A JP 2019514913 A5 JP2019514913 A5 JP 2019514913A5
Authority
JP
Japan
Prior art keywords
agent
optionally
polypeptide
antibody
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514913A (ja
JP7160683B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030454 external-priority patent/WO2017190148A1/en
Publication of JP2019514913A publication Critical patent/JP2019514913A/ja
Publication of JP2019514913A5 publication Critical patent/JP2019514913A5/ja
Application granted granted Critical
Publication of JP7160683B2 publication Critical patent/JP7160683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556332A 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物 Active JP7160683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329666P 2016-04-29 2016-04-29
US62/329,666 2016-04-29
PCT/US2017/030454 WO2017190148A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Publications (3)

Publication Number Publication Date
JP2019514913A JP2019514913A (ja) 2019-06-06
JP2019514913A5 true JP2019514913A5 (enExample) 2020-05-28
JP7160683B2 JP7160683B2 (ja) 2022-10-25

Family

ID=60161169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556332A Active JP7160683B2 (ja) 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物

Country Status (9)

Country Link
US (1) US10934355B2 (enExample)
EP (1) EP3448421B1 (enExample)
JP (1) JP7160683B2 (enExample)
CA (1) CA3019841A1 (enExample)
ES (1) ES2903210T3 (enExample)
PL (1) PL3448421T3 (enExample)
PT (1) PT3448421T (enExample)
SI (1) SI3448421T1 (enExample)
WO (1) WO2017190148A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
WO2020157122A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
US20200386772A1 (en) * 2019-06-05 2020-12-10 Mark D. Noar Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
JP7706169B2 (ja) * 2020-02-26 2025-07-11 上海科技大学 抗コロナウイルスにおけるジスルフィラムの使用
WO2022126259A1 (en) * 2020-12-14 2022-06-23 Uti Limited Partnership Treatment of peritoneal, pleural, and pericardium adhesions
US12011163B2 (en) 2021-01-22 2024-06-18 Cilag Gmbh International Prediction of tissue irregularities based on biomarker monitoring
US12440285B2 (en) 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US20220233135A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Prediction of adhesions based on biomarker monitoring
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
CN113244400B (zh) * 2021-05-21 2022-12-16 华北理工大学 一种C5aRA在制备治疗和/或预防腹腔粘连的产品中的应用
US20250333482A1 (en) * 2021-11-05 2025-10-30 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Modulators of mesothelial ecm movement

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639468A (en) 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
WO1999020297A1 (en) 1997-10-16 1999-04-29 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prevention and treatment of adhesion formation
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
WO2003063904A2 (en) * 2002-01-29 2003-08-07 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Tissue adhesion formation control
US20040131600A1 (en) 2002-03-11 2004-07-08 Diamond Michael P. Method of preventing adhesions by apoptosis of adhesion peritoneal cells
JP4224586B2 (ja) 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
AU2005299482A1 (en) * 2004-10-25 2006-05-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for lowering HIF-1 mediated gene expression
EP2322560B1 (en) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
WO2007008300A2 (en) * 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
JP5194207B2 (ja) 2005-08-11 2013-05-08 エーディーイー、セラピューティックス、インコーポレーテッド 腹腔内グルタミンによる術後癒着形成の減少
CA2658584A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
HRP20150074T1 (hr) * 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
ES2325724B1 (es) * 2008-03-11 2010-05-31 FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular.
CA2756393C (en) 2009-03-24 2017-06-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
JP2011195574A (ja) * 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールa誘導体を含有するhif阻害剤
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
US8962577B2 (en) * 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CN105189556A (zh) 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法

Similar Documents

Publication Publication Date Title
Tripathi et al. HMGB1 protein as a novel target for cancer
JP2006525796A5 (enExample)
EP3448421B1 (en) Methods and compositions for the prevention and treatment of surgical adhesions
Canavan et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review
JP2006513992A5 (enExample)
JP2011519277A5 (enExample)
Tsao et al. NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression
WO2018187740A1 (en) Bioorthogonal compositions
US20170020917A1 (en) Process for the identification of compounds for treating cancer
Grist et al. Neutrophils and viral-induced neurologic disease
JP2012522508A5 (enExample)
JP2017113019A5 (enExample)
Cirelli et al. AAV2/1-TNFR: Fc gene delivery prevents periodontal disease progression
JPH11504036A (ja) ケモカイン結合タンパク質およびその使用
JPH07106986B2 (ja) Tnfおよびil−1の作用を調節する組成物および方法
JP2013504603A5 (enExample)
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
Zhu et al. Low‐intensity pulsed ultrasound alleviates doxorubicin‐induced cardiotoxicity via inhibition of S100a8/a9‐mediated cardiac recruitment of neutrophils
Mitra et al. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease
Messora et al. Rosuvastatin promotes benefits on induced periodontitis in hypertensive rats
Maronek et al. The citrullination-neutrophil extracellular trap axis in chronic diseases
JP2010513308A (ja) 血管新生向性ペプチド
Chen et al. Neutrophil extracellular traps promote AIM2-dependent microglial Pyroptosis following stroke
CN111182925A (zh) 阳离子核酸清除剂及其用途
US9492470B2 (en) Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells